Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.

Takashi WadaKazumi Mori-AnaiAkiko TakahashiTakahiro MatsuiMasaya InagakiMitsutaka IidaKen MaruyamaHidetaka Tsuda

Published in: Journal of diabetes investigation (2022)

This study suggests that canagliflozin safely reduces the risk of end-stage renal disease in Japanese chronic kidney disease patients with type 2 diabetes mellitus.

Keyphrases

end stage renal disease
chronic kidney disease
double blind
placebo controlled
peritoneal dialysis
phase iii
clinical trial
open label
phase ii
ejection fraction
newly diagnosed
study protocol
squamous cell carcinoma
patient reported outcomes
patient reported